COVID-19 
, COVID-19 Related Compounds
TDZD-8
- Catalog Number : C5138
- Number :
-
Size:
Qty : - Price : 0 詢價
- Stock : Request
-
Introduction
Description of TDZD-8: TDZD-8 is a serine/threonine glycogen synthase kinase 3beta (GSK-3beta) inhibitor. GSK-3beta is abundant in the central nervous system, particularly in the hippocampus, and plays a pivotal role in the pathophysiology of a number of diseases, including neurodegeneration. TDZD-8 protects the brain against I/R injury by inhibiting GSK-3beta activity. TDZD-8 decreased proliferation and induced apoptosis of GL261 glioblastoma cells in vitro, delayed tumor growth in vivo, and augmented animal survival. These effects were associated with an early activation of extracellular signal-regulated kinase (ERK) pathway and increased expression of EGR-1 and p21 genes. Treatment of glioblastoma stem cells with TDZD-8 resulted in an inhibition of proliferation and self-renewal of these cells. For the detailed information about the solubility of TDZD-8 in water, the solubility of TDZD-8 in DMSO, the solubility of TDZD-8 in PBS buffer, the animal experiment（test） of TDZD-8,the in vivo,in vitro and clinical trial test of TDZD-8,the cell experiment（test） of TDZD-8,the IC50, EC50 and Affinity of TDZD-8, please contact DC Chemicals.
General Information
| Cas No. | 327036-89-5 |
|---|---|
| Purity | >98% |
| Molecular Weight | 222.26 |
| Formula | C10H10N2O2S |
| Solubility | DMSO : ≥ 100 mg/mL |
| Storage instruction | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
.png)